



PTO/SB/08A (08-009)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Application Number	10/050,200
Filing Date	January 18, 2022
First Named Inventor	FOURIE, et. al.
Group Art Unit	1646
Examiner Name	
Attorney Docket Number	ORT-1417

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENT						
Examiner Initials	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Office ³	Number ⁴			
dh		WO	00/05256	A1	DU PONT PHARMACEUTICALS COMPANY	02/03/2000


Examiner W. D. Fitch Date Considered 06/16/04

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if applicable. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, 1100 L Street, N.W., Washington, D.C. 20591.

Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Application Number

10,050,200

Filing Date

January 18, 2002

First Named Inventor

FOURIE, et. al.

Group Art Unit

1646

Examiner Name

Attorney Docket Number

ORT-1417

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
MR	1	ABBASZADE, I., et. al., "Cloning and Characterization of ADAMTS11, an Aggrecanase from the ADAMTS Family", The Journal of Biological Chemistry, 1999 Vol 274(33):23443-23450.	
MR	2	BAILEY, S., et al., "Selective Inhibition of Low Affinity IgE Receptor (CD23) Processing: P1' Bicyclomethyl Substituents," Bioorganic & Medicinal Chemistry Letters 1999 9:3165-3170.	
MR	3	CATERSON, B., et. al., "Mechanisms involved in cartilage proteoglycan catabolism," Matrix Biology 2000 19:333-344.	
MR	4	CHEN, J., et. al., "Design, Synthesis, Activity, And Structure Of A Novel Class Of Matrix Metalloproteinase Inhibitors Containing A Heterocyclic P2'-P3' Amide Bond Isostere," Bioorganic & Medicinal Chemistry Letters, 1996 Vol 6(13):1601-1606	
MR	5	HORBER, C., et. al., "Truncation of the amino-terminus of the recombinant aggrecan rAgg1(mut) leads to reduced cleavage at the aggrecanase site. Efficient aggrecanase catabolism may depend on multiple substrate interactions," Matrix Biology 2000 19:533-543.	
MR	6	LOHMANDER, L. S., et al., "The Structure of Aggrecan Fragments in Human Synovial Fluid," Arthritis & Rheumatism, 1993 36(9):1214-1222	
MR	7	PRATTA, M., et. al., "Age-related Changes in Aggrecan Glycosylation Affect Cleavage by Aggrecanase," Journal of Biological Chemistry, 2000 Vol. 275(50):39098-39102.	
MR	8	PRIMAKOFF, P., and MYLES, D. G., "The Adam gene family surface proteins with adhesion and protease activity," Trends Genet 2000 16(2):83-87	
MR	9	ROGHANI, M., et. al., "Metalloprotease-Disintegrin MDC9: Intracellular Maturation and Catalytic Activity," Journal of Biological Chemistry, 1999 Vol 274(6):3531-3540.	
MR	10	SANDY, J.D., et. al., "The intermediates of aggrecanase-dependent cleavage of aggrecan in rat chondrosarcoma cells treated with interleukin-1," Biochemistry Journal 2000 351:161-166	
MR	11	TANG, B. L., and Hong, W., "ADAMTS: A novel family of proteases with an ADAM protease domain and thrombospondin 1 repeats," FEBS Letters 445:223-225 1999	
MR	12	TORTORELLA, M. D., et. al., "Sites of Aggrecan Cleavage by Recombinant Human Aggrecanase-1 (ADAMTS-4)," Journal of Biological Chemistry 2000 Vol. 275(24):18568-18573.	
MR	13	TORTORELLA, M. D., et. al., "Purification and Cloning of Aggrecanase-1: A Member of the ADAMTS Family of Proteins," 1999 Vol 284:1664-1666	
MR	14	Medline 98403880, 1998	
MR	15	Medline 99367476, 1999	

Examiner
Signature

M. L. Williams

Date
Considered

06/16/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.